

1-(1-Benzofuran-2-yl)ethanone O-(2-chlorobenzoyl)oxime

Nazan Ocak İskeleli,^a Canan Kazak,^a Cumhuri Kırılmış^b and Murat Koca^{b*}^aDepartment of Physics, Faculty of Arts and Sciences, Ondokuz Mayıs University, TR-55139 Kurupelit-Samsun, Turkey, and ^bDepartment of Chemistry, Faculty of Science and Art, Firat University, TR-23169 Elazı, Turkey

Correspondence e-mail: nocak@omu.edu.tr

Key indicators

Single-crystal X-ray study
T = 293 K
Mean $\sigma(\text{C}-\text{C}) = 0.002 \text{ \AA}$
Disorder in main residue
R factor = 0.032
wR factor = 0.078
Data-to-parameter ratio = 14.4For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.The title compound, $\text{C}_{17}\text{H}_{12}\text{ClNO}_3$, displays the characteristic features of benzofuran derivatives. The molecule is not planar. Intermolecular $\text{C}-\text{H}\cdots\text{O}$ interactions help to stabilize the structure.

Received 18 March 2005


Accepted 29 March 2005


Online 31 March 2005

Comment

Oxime derivatives are bioactive compounds. It has been reported that free oximes and their ethers or esters show notably high activities (Massolini *et al.*, 1994; Demirayak *et al.*, 2002) when used as medicines and pesticides. In asymmetric synthesis, these compounds are good precursors for chiral amines. In most cases, they are synthesized in two steps, *viz.* condensation between a carbonyl compound and hydroxylamine followed by alkylation with an alkyl halide in the presence of a base under phase-transfer catalytic (PTC) conditions. These compounds have also been prepared by condensation of alkyl hydroxylamines with carbonyl compounds (Chumbao *et al.*, 2003; Abele & Lukevics 2000; Itsuna *et al.*, 1990; Abele *et al.*, 2000; Arıcı *et al.*, 2004a,b).

The benzofuran ring system of the title compound, (I), is planar, with a maximum deviation from the plane of 0.0042 (25) Å for C15 (Fig. 1). In the benzofuran system, all bond lengths agree with values reported in the literature (Allen, 2002). The dihedral angle between the benzofuran ring system and chlorobenzoyl group is 61.50 (4)°. The C1—Cl bond distance is close to the values reported in the literature (Allen, 2002).




Figure 1

The molecule of (I), showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 50% probability level and H atoms are shown as small spheres of arbitrary radii. Both components of the disordered methyl group are shown.

Experimental

For the synthesis of (I), 2-acetylbenzofuranoxime (1.75 g, 10 mmol), triethylamine (2 ml) and dry THF (100 ml) were stirred at room temperature for 1 h. To this solution, 2-chlorobenzoylchloride (1.75 g, 10 mmol) was added dropwise and the mixture was stirred for another 1 h at room temperature. The reaction mixture was poured into water (250 ml) and precipitated twice from water. The solid was filtered off and recrystallized from acetone. Yield 2.92 g, 93.3%.

Crystal data

$C_{17}H_{12}ClNO_3$	$D_x = 1.424 \text{ Mg m}^{-3}$
$M_r = 313.73$	Mo $K\alpha$ radiation
Monoclinic, $P2_1/n$	Cell parameters from 19 482 reflections
$a = 11.9515 (9) \text{ \AA}$	$\theta = 1.7\text{--}27.9^\circ$
$b = 8.1082 (4) \text{ \AA}$	$\mu = 0.27 \text{ mm}^{-1}$
$c = 15.1665 (10) \text{ \AA}$	$T = 293 (2) \text{ K}$
$\beta = 95.359 (6)^\circ$	Prism, colourless
$V = 1463.29 (16) \text{ \AA}^3$	$0.55 \times 0.32 \times 0.28 \text{ mm}$
$Z = 4$	

Data collection

Stoe IPDS-II diffractometer	2200 reflections with $I > 2\sigma(I)$
φ scans	$R_{\text{int}} = 0.062$
Absorption correction: integration	$\theta_{\text{max}} = 26.0^\circ$
(<i>X-RED32</i> ; Stoe & Cie, 2002)	$h = -14 \rightarrow 14$
$T_{\text{min}} = 0.883$, $T_{\text{max}} = 0.951$	$k = -10 \rightarrow 9$
19 932 measured reflections	$l = -18 \rightarrow 18$
2869 independent reflections	

Refinement


Refinement on F^2	$w = 1/[\sigma^2(F_o^2) + (0.0375P)^2 + 0.1959P]$
$R[F^2 > 2\sigma(F^2)] = 0.032$	where $P = (F_o^2 + 2F_c^2)/3$
$wR(F^2) = 0.078$	$(\Delta/\sigma)_{\text{max}} < 0.001$
$S = 1.02$	$\Delta\rho_{\text{max}} = 0.17 \text{ e \AA}^{-3}$
2869 reflections	$\Delta\rho_{\text{min}} = -0.19 \text{ e \AA}^{-3}$
199 parameters	Extinction correction: none
H-atom parameters constrained	

Table 1

Hydrogen-bond geometry (\AA , $^\circ$).

$D\text{--}H\cdots A$	$D\text{--}H$	$H\cdots A$	$D\cdots A$	$D\text{--}H\cdots A$
$C3\text{--}H3\cdots O1^i$	0.93	2.50	3.213 (2)	134
$C16\text{--}H16\cdots O1^i$	0.93	2.55	3.427 (2)	159

Symmetry codes: (i) $-x + \frac{3}{2}, y + \frac{1}{2}, -z + \frac{1}{2}$; (ii) $x, y - 1, z$.


Figure 2

A packing diagram for (I), showing the $C\text{--}H\cdots O$ hydrogen bonding interactions as dashed lines. H atoms not involved in hydrogen bonding have been omitted for clarity. [Symmetry code: (i) $\frac{3}{2} - x, \frac{1}{2} + y, \frac{1}{2} - z$.]

All H atoms were located in difference maps and subsequently treated as riding atoms, with $C\text{--}H = 0.93 \text{ \AA}$ (aromatic) and 0.96 \AA (CH_3), and with $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C}_{\text{aromatic}})$ and $1.5U_{\text{eq}}(\text{C}_{\text{CH}_3})$. The methyl group is disordered over two positions with equal occupancy.

Data collection: *X-AREA* (Stoe & Cie, 2002); cell refinement: *X-AREA*; data reduction: *X-RED32* (Stoe & Cie, 2002; program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *ORTEP-III* (Burnett & Johnson, 1996), *ORTEP-3 for Windows* (Farrugia, 1997) and *PLATON* (Spek, 2003); software used to prepare material for publication: *WinGX* (Farrugia, 1999).

References

- Abele, E., Abele, R., Popelis, J. & Lukevics, E. (2000). *Org. Prep. Proc. Int.* **32**, 153–159.
- Abele, E. & Lukevics, E. (2000). *Org. Prep. Proc. Int.* **32**, 237–264.
- Allen, F. (2002). *Acta Cryst.* **B58**, 380–388.
- Ancı, C., Ülkü, D., Kırılış, C., Koca, M. & Ahmedzade, M. (2004a). *Acta Cryst.* **E60**, o941–o942.
- Ancı, C., Ülkü, D., Kırılış, C., Koca, M. & Ahmedzade, M. (2004b). *Acta Cryst.* **E60**, o1211–o1212.
- Burnett, M. N. & Johnson, C. K. (1996). Report ORNL-6895. Oak Ridge National Laboratory, Tennessee, USA.
- Chumbao, L., Hang, Z., Yi, C., Shuanming, Z., Zheyuan, Z., Michael, C. K. C. & Albert, S. C. C. (2003). *Synth. Commun.* **33**, 543–546.
- Demirayak, S., Ucucu, U., Benkli, K., Gundogdu-Karaburun, N., Karaburun, A. C., Akar, D., Karabacak, M. & Kiraz, N. (2002). *Farmaco*, **57**, 609–612.
- Farrugia, L. J. (1997). *J. Appl. Cryst.* **30**, 565.
- Farrugia, L. J. (1999). *J. Appl. Cryst.* **32**, 837–838.
- Itsuna, S., Sakurai, Y., Shimizu, K. & Ito, K. (1990). *J. Chem. Soc. Perkin. Trans.* **1**, pp. 1859–1863.
- Massolini, G., Carmellino, M. L. & Baruffini, A. (1994). *Farmaco*, **49**, 747–749.
- Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.
- Spek, A. L. (2003). *J. Appl. Cryst.* **36**, 7–13.
- Stoe & Cie (2002). *X-AREA* (Version 1.18) and *X-RED32* (Version 1.04). Stoe & Cie, Darmstadt, Germany.